Open AccessSerum IL-33 as a biomarker in different diseases: useful parameter or much need for clarification?
Author(s) -
Stefan Erfurt,
Meike Hoffmeister,
Stefanie Oess,
Katharina Asmus,
Oliver Ritter,
Susann Patschan,
Daniel Patschan
Publication year - 2021
Publication title -
journal of circulating biomarkers
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.846
H-Index - 11
ISSN - 1849-4544
DOI - 10.33393/jcb.2021.2327
Subject(s) - biomarker , medicine , adipose tissue , interleukin 6 , immune system , innate immune system , immunology , bioinformatics , inflammation , biology , biochemistry
Interleukin-33 (IL-33), a member of the IL-1 family, is critically involved in the modulation of the activity of a diverse range of immunocompetent cells. Essential roles have been implicated in cardioprotection, in both innate and adaptive immune responses in mucosal organs, and in the maintenance of adipose tissue cells. Over the past 10 years, several studies evaluated the usability of IL-33 as a biomarker in diseases of inflammatory and noninflammatory origin. Our group is currently evaluating the predictive role of serum IL-33 in acute kidney injury (AKI). The aim of the article is to discuss selected studies on IL-33 in different diseases and its potential role as a biomarker molecule.